MacLean Michael F — SEC Form 4 filings
SEC reporting owner CIK 1383731. 19 Form 4 filings on record with FilingPulse; latest filed 2026-04-03.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-01-23 to 2026-04-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 13 filings — 409,721 shares, $15,128,176 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: sale of 104,245 shares @ $35.72 ($3,723,141) in Avidity Biosciences, Inc., filed 2024-06-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. (RNAM) | Chief Financial Officer | 15 | — | 17 legs · 409,721 sh · $15,128,176 | 25 |
| Verve Therapeutics, Inc. (VERV) | Director | 3 | — | — | 4 |
| Camp4 Therapeutics Corp (CAMP) | Director | 1 | — | — | 1 |
Form 4 filings — MacLean Michael F
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-03 | 4 | Camp4 Therapeutics Corp (CAMP) | Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Avidity Biosciences, Inc. (RNAM) | Disposition to issuer (D): 133,977 · Disposition to issuer (D): 92,000 (derivative) · Disposition to issuer (D): 131,250 (derivative) · Disposition to issuer (D): 148,000 (derivative) · Disposition to issuer (D): 60,125 (derivative) · Disposition to issuer (D): 106,000 (derivative) · +1 more | EDGAR |
| 2026-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 1,807 @ $72.45 · Sale (S): 2,735 @ $72.45 | EDGAR |
| 2026-01-09 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 1,974 @ $72.23 | EDGAR |
| 2025-08-15 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 30,914 @ $42.73 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Disposition to issuer (D): 136,139 (derivative) · Disposition to issuer (D): 42,200 (derivative) | EDGAR |
| 2025-06-06 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 42,200 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 7,935 @ $31.06 | EDGAR |
| 2025-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 1,622 @ $28.59 · Sale (S): 1,665 @ $28.59 | EDGAR |
| 2025-01-08 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 11,151 @ $32.66 | EDGAR |
| 2024-11-08 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 27,262 @ $46.22 · Option exercise (M): 65,182 @ $8.82 · Sale (S): 65,182 @ $45.33 · Option exercise (M): 13,875 @ $6.57 · Sale (S): 13,875 @ $45.33 · Option exercise (M): 65,182 (derivative) @ $0 · +1 more | EDGAR |
| 2024-09-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Sale (S): 11,510 @ $44 · Grant/award (A): 25,000 @ $0 | EDGAR |
| 2024-06-28 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 136,139 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 25,000 @ $0 · Sale (S): 11,228 @ $39.13 · Grant/award (A): 25,000 @ $0 | EDGAR |
| 2024-06-14 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 104,245 @ $8.82 · Sale (S): 104,245 @ $35.72 · Option exercise (M): 104,245 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 75,000 @ $8.82 · Sale (S): 75,000 @ $28.28 · Option exercise (M): 75,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 40,000 @ $8.82 · Sale (S): 40,000 @ $24.52 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 22,500 @ $0 · Sale (S): 1,616 @ $10.13 · Grant/award (A): 106,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1383731 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →